BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1586 related articles for article (PubMed ID: 28652656)

  • 1. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis.
    Matusiewicz M; Neubauer K; Bednarz-Misa I; Gorska S; Krzystek-Korpacka M
    World J Gastroenterol; 2017 Jun; 23(22):4039-4046. PubMed ID: 28652656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The diagnostic and evaluation value of plasma interleukin 9 in the mucosal healing in patients with inflammatory bowel disease treated with biological agents].
    Ye YL; Hu T; Xu LJ; Zhang LP; Yin J; Yu Q; Pang Z
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1483-1489. PubMed ID: 37198111
    [No Abstract]   [Full Text] [Related]  

  • 4. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing.
    Chang J; Leong RW; Wasinger VC; Ip M; Yang M; Phan TG
    Gastroenterology; 2017 Sep; 153(3):723-731.e1. PubMed ID: 28601482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth differentiation factor-15 serum concentrations reflect disease severity and anemia in patients with inflammatory bowel disease.
    Tonkic A; Kumric M; Akrapovic Olic I; Rusic D; Zivkovic PM; Supe Domic D; Sundov Z; Males I; Bozic J
    World J Gastroenterol; 2024 Apr; 30(13):1899-1910. PubMed ID: 38659482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble ST2: a new and promising activity marker in ulcerative colitis.
    Díaz-Jiménez D; Núñez LE; Beltrán CJ; Candia E; Suazo C; Alvarez-Lobos M; González MJ; Hermoso MA; Quera R
    World J Gastroenterol; 2011 May; 17(17):2181-90. PubMed ID: 21633527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity.
    Boga S; Alkim H; Koksal AR; Ozagari AA; Bayram M; Tekin Neijmann S; Sen I; Alkim C
    J Investig Med; 2016 Jun; 64(5):1016-24. PubMed ID: 27001944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is ischemia modified albumin a disease activity marker for inflammatory bowel diseases?
    Kaplan M; Yuksel M; Ates I; Kilic ZM; Kilic H; Kuzu UB; Kayacetin E
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1120-5. PubMed ID: 26642816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
    Grimstad T; Skoie IM; Doerner J; Isaksen K; Karlsen L; Aabakken L; Omdal R; Putterman C
    Scand J Gastroenterol; 2017 Apr; 52(4):420-424. PubMed ID: 28040992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonenzymatic Serum Antioxidant Capacity in IBD and Its Association with the Severity of Bowel Inflammation and Corticosteroids Treatment.
    Neubauer K; Kempinski R; Matusiewicz M; Bednarz-Misa I; Krzystek-Korpacka M
    Medicina (Kaunas); 2019 Apr; 55(4):. PubMed ID: 30986917
    [No Abstract]   [Full Text] [Related]  

  • 12. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
    Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definition and evaluation of mucosal healing in clinical practice.
    Mazzuoli S; Guglielmi FW; Antonelli E; Salemme M; Bassotti G; Villanacci V
    Dig Liver Dis; 2013 Dec; 45(12):969-77. PubMed ID: 23932331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.
    Lee SH; Kim MJ; Chang K; Song EM; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    BMC Gastroenterol; 2017 Oct; 17(1):110. PubMed ID: 29061121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD.
    Dierckx T; Verstockt B; Vermeire S; van Weyenbergh J
    J Crohns Colitis; 2019 Mar; 13(3):389-394. PubMed ID: 30312386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
    Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
    Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Potential of Systemic Eosinophil-Associated Cytokines and Growth Factors in IBD.
    Neubauer K; Matusiewicz M; Bednarz-Misa I; Gorska S; Gamian A; Krzystek-Korpacka M
    Gastroenterol Res Pract; 2018; 2018():7265812. PubMed ID: 30147719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease.
    Cordes F; Demmig C; Bokemeyer A; Brückner M; Lenze F; Lenz P; Nowacki T; Tepasse P; Schmidt HH; Schmidt MA; Cichon C; Bettenworth D
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00134. PubMed ID: 32352717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test.
    Nakarai A; Kato J; Hiraoka S; Kuriyama M; Akita M; Hirakawa T; Okada H; Yamamoto K
    Am J Gastroenterol; 2013 Jan; 108(1):83-9. PubMed ID: 23007005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rectal Delivery of a DNAzyme That Specifically Blocks the Transcription Factor GATA3 and Reduces Colitis in Mice.
    Popp V; Gerlach K; Mott S; Turowska A; Garn H; Atreya R; Lehr HA; Ho IC; Renz H; Weigmann B; Neurath MF
    Gastroenterology; 2017 Jan; 152(1):176-192.e5. PubMed ID: 27639807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.